Medigrowth Australia has named former Canopy Growth manager Dr Ashleigh Osborne as its national medical lead.
Osborne spent four-and-a-half years at Canopy, joining the medical science liaison team in NSW in April 2020 before rising to country medical affairs manager in October 2022.
Medigrowth chief executive Adam Guskich said Osborne would bring a “passion” for cannabinoid-based medicine to the company, and described her work in destigmatising medicinal cannabis through scientific communication as “truly inspiring”.
He added Osborne’s expertise in regulatory affairs, clinical research and multiple therapeutic areas would be “invaluable” to Medigrowth.
The People’s Plant
A rush of support in the final hours of a Birchal crowdsource funding campaign saw The People’s Plant nudge past the A$1 million mark.
The Sunshine Coast-based cultivator had raised $770,000 from 400 investors on the morning of the final day of the offer, but ended with $1,031,585 from 641 investors.
The company had targeted a minimum of $250,000 and a maximum of $2m.
Co-founder Rebecca Risby-Jones said she was “thrilled” by the response.
Epsilon Healthcare
The Deed of Company Arrangement (DOCA) for Epsilon Pharma and Epsilon Clinics has been completed, but management is continuing to “address matters” in relation to the parent company, Epsilon Healthcare, the company has said.
The DOCA was put forward in June by deputy chairman Alan Beasley and chief executive Peter Giannopoulos – and approved by creditors – after a seven-month period in voluntary administration.
In an update to the ASX, Epsilon said that while the DOCA for its subsidiaries has been finalised, work remains to be done for Epsilon Healthcare. It did not disclose details of the matters that need resolving.
“[We] will advise about specific outcomes and next steps in due course,” the company said. “The Epsilon board would like to sincerely thank clients and supply partners for their patience and support during the regrettable period of voluntary administration.
“With the completion of the DOCA, the management and board can now refocus on supporting its people to deliver exceptional services and care to clients and patients.”
Byron Bay Bio
Byron Bay Bio has raised A$233,168 from 122 investors with one day of its Birchal crowdsource funding campaign to run.
The technology-cum-product supplier set a maximum target of $1.5m, with an initiative to patent seeds through DNA genome sequencing and the registration of an over-the-counter CBD muscle balm among its goals.
